5-(nonyloxy)tryptamine has been researched along with Glial Cell Tumors in 1 studies
5-(nonyloxy)tryptamine: a 5-HT1D beta serotonin receptor agonist; structure given in first source
5-nonyloxytryptamine : A tryptamine derivative that consists of serotonin bearing an additional O-nonyl substituent. 5-HT1B selective agonist, several times more potent than sumatriptan and inactive as a 5-HT1A agonist (Ki at 5-HT1B = 1 nM, selectivity over 5-HT1A > 300-fold).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dupuis, DS | 1 |
| Perez, M | 1 |
| Halazy, S | 1 |
| Colpaert, FC | 1 |
| Pauwels, PJ | 1 |
1 other study available for 5-(nonyloxy)tryptamine and Glial Cell Tumors
| Article | Year |
|---|---|
Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses.
Topics: Animals; Autoradiography; Binding, Competitive; Brain Chemistry; Dimerization; Glioma; GTP-Binding P | 1999 |